[go: up one dir, main page]

MX2023008966A - Anticuerpo biespecifico. - Google Patents

Anticuerpo biespecifico.

Info

Publication number
MX2023008966A
MX2023008966A MX2023008966A MX2023008966A MX2023008966A MX 2023008966 A MX2023008966 A MX 2023008966A MX 2023008966 A MX2023008966 A MX 2023008966A MX 2023008966 A MX2023008966 A MX 2023008966A MX 2023008966 A MX2023008966 A MX 2023008966A
Authority
MX
Mexico
Prior art keywords
bispecific antibody
antigen
binding moiety
amino acid
acid sequence
Prior art date
Application number
MX2023008966A
Other languages
English (en)
Inventor
Zhengping Zhang
Liangliang Wang
Congcong Sun
Rongjuan Zhao
Yimeng Li
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2023008966A publication Critical patent/MX2023008966A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporciona un anticuerpo biespecífico, que comprende una primera fracción de unión a antígeno y una segunda fracción de unión a antígeno, en donde un dominio emparejado de la primera fracción de unión a antígeno comprende una secuencia de aminoácidos de HLA-I a3 manipulado y una secuencia de aminoácidos de ß2M manipulada. También se proporciona un método de expresión para el anticuerpo biespecífico, un polinucleótido que codifica el anticuerpo biespecífico, un vector y una célula hospedadora que contiene el polinucleótido, una composición farmacéutica que contiene el anticuerpo biespecífico, una proteína de fusión y un conjugado. El anticuerpo biespecífico proporcionado puede prevenir o atenuar los emparejamientos incorrectos entre cadenas pesadas y ligeras de diferentes especificidades.
MX2023008966A 2021-02-07 2022-01-27 Anticuerpo biespecifico. MX2023008966A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110178932 2021-02-07
CN202110937430 2021-08-16
PCT/CN2022/074133 WO2022166728A1 (zh) 2021-02-07 2022-01-27 双特异性抗体

Publications (1)

Publication Number Publication Date
MX2023008966A true MX2023008966A (es) 2023-09-29

Family

ID=82740913

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008966A MX2023008966A (es) 2021-02-07 2022-01-27 Anticuerpo biespecifico.

Country Status (12)

Country Link
US (1) US20240092899A1 (es)
EP (1) EP4303231A4 (es)
JP (1) JP2024507693A (es)
KR (1) KR20230141817A (es)
CN (2) CN118063620A (es)
AU (1) AU2022215712A1 (es)
BR (1) BR112023015217A2 (es)
CA (1) CA3210307A1 (es)
IL (1) IL304800A (es)
MX (1) MX2023008966A (es)
TW (1) TW202233694A (es)
WO (1) WO2022166728A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3124770A1 (en) * 2018-12-24 2020-07-02 Sanofi Pseudofab-based multispecific binding proteins
CA3231335A1 (en) * 2021-09-08 2023-03-16 Sergei Aleksandrovich LEGOTSKII Bispecific antibody comprising a heterodimer based on mhc proteins
WO2023051680A1 (zh) * 2021-09-30 2023-04-06 正大天晴药业集团股份有限公司 针对免疫检查点的双特异性抗体
CN120344558A (zh) * 2022-12-08 2025-07-18 上海星赛生物科技有限公司 双特异性/多特异性抗体及其用途
WO2025213057A1 (en) * 2024-04-04 2025-10-09 Fletcher Biosciences, Inc. Engineered major histocompatibility complex molecules and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381794B2 (en) * 2004-03-08 2008-06-03 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
EP2935328B1 (en) * 2012-12-21 2018-10-10 F.Hoffmann-La Roche Ag Disulfide-linked multivalent mhc class i comprising multi-function proteins
SG10201901057UA (en) 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
US20190046648A1 (en) * 2016-03-03 2019-02-14 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN111094333A (zh) * 2017-06-01 2020-05-01 斯图加特大学 异源二聚化的Ig结构域
US12195529B2 (en) * 2017-06-21 2025-01-14 Gsbio, Llc Heterodimeric bispecific antibodies
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
EA202090812A1 (ru) * 2017-09-22 2020-08-07 Уси Байолоджикс Аэлэнд Лимитед Новые биспецифические полипептидные комплексы
EP3768705A1 (en) * 2018-03-22 2021-01-27 Universität Stuttgart Multivalent binding molecules
AU2019247229A1 (en) 2018-04-05 2020-10-15 Novartis Ag Trispecific binding molecules against cancers and uses thereof
KR20200143730A (ko) * 2018-04-17 2020-12-24 인벤라 인코포레이티드 3가 삼중 특이성 항체 구조물
WO2020257191A1 (en) * 2019-06-19 2020-12-24 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof

Also Published As

Publication number Publication date
IL304800A (en) 2023-09-01
TW202233694A (zh) 2022-09-01
EP4303231A4 (en) 2025-02-26
CN118063620A (zh) 2024-05-24
EP4303231A1 (en) 2024-01-10
AU2022215712A1 (en) 2023-09-07
WO2022166728A1 (zh) 2022-08-11
JP2024507693A (ja) 2024-02-21
CN116964084A (zh) 2023-10-27
KR20230141817A (ko) 2023-10-10
US20240092899A1 (en) 2024-03-21
CA3210307A1 (en) 2022-08-11
BR112023015217A2 (pt) 2023-11-07

Similar Documents

Publication Publication Date Title
MX2023008966A (es) Anticuerpo biespecifico.
CL2023000499A1 (es) Proteínas que comprenden dominios de unión al antígeno de la hk2 y sus usos.
AR124692A2 (es) Anticuerpos anti-cd40 y sus usos
BR112021016984A2 (pt) Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação
PE20211707A1 (es) Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anticgrp
MX2022002342A (es) Composiciones y metodos para suministro de acidos nucleicos a celulas.
CL2008003778A1 (es) Anticuerpo bivalente biespecifico que comprende a) una cadena ligera y pesada que se une a un primer antigeno, y b) una cadena ligera y pesada que se une a un segundo antigeno en la que los dominios cl y ch1 estan cambiados el uno por el otro, y donde ademas los dominios ch3 de ambas cadenas pesadas se alteran mediante el reemplazo de residuos aminoacidicos, de forma que se genera una protuberancia en uno de los ch3, y una cavidad en el otro ch3; metodo de preparacion de dicho anticuerpo; celula huesped que comprende vectores codificantes de dicho anticuerpo; y composicion que lo comprende.
PE20240761A1 (es) Proteinas de union a psma y usos de estas
PE20141028A1 (es) Nuevos moduladores y metodos para su uso
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
NI201800113A (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
MX2023014679A (es) Peptidos grapados y metodos para su obtencion.
MX2024001067A (es) Composicion farmaceutica y uso.
MX2023014453A (es) Uso de anticuerpos anti-antigeno 4 del linfocito t citotoxico (anti-ctla-4).
AR115419A1 (es) Anticuerpos anti-tmeff2 monoespecíficos y multiespecifícos y sus usos
CL2024003622A1 (es) Proteína de unión a antígeno tigit; método de producción; composición farmacéutica; y su uso.
CO2017013303A2 (es) Inmunoglobulinas conjugadas en cys80
MX2022000456A (es) Anticuerpos biespecificos simetricos tetravalentes.
PE20230075A1 (es) Anticuerpos anti-flt3 y composiciones
AR123537A1 (es) Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca
MX2024014591A (es) Anticuerpo anti-bdca2 y uso del mismo
MX2019010555A (es) Anticuerpo anti-pd-l1 para detectar pd-l1.
CL2024001751A1 (es) Complejos polipeptídicos de unión a antígeno que contienen dominios extracelulares de ligandos tnfsf
AR126001A1 (es) Anticuerpos y composiciones anti-nkg2a
CL2024001075A1 (es) Administración subcutánea de anticuerpos acopladores a linfocitos t de unión a cd19